ESR1 and cancer: Interval cancers with DBT (vs DM) less frequently had favorable characteristics: estrogen receptor–positive or progesterone receptor–positive (72.3% vs 84.8%, respectively) and ERBB2-negative (79.2% vs 86.2%, respectively).